Abstract
Breast cancer constitutes one of the most commonly diagnosed malignancies among the female population globally, and its development and progression are intimately connected with functional anomalies in the DNA damage response (DDR) pathway. A synthetic lethality basis for the clinical use of poly (ADP-ribose) polymerase inhibitors (PARPi) is provided by homologous recombination deficiency (HRD). Several PARPi, such as olaparib and talazoparib, are approved as monotherapies for specific populations of patients with germline BRCA-mutated, HER2-negative breast cancer. They exert considerable efficacy by blocking PARP catalytic activity, interfering with liquid–liquid phase separation, and causing PARP-DNA entrapment. Nevertheless, sustained therapeutic benefits from PARPi are markedly diminished once acquired resistance develops. The underlying resistance mechanisms, which include BRCA1/2 reversion mutations, upregulation of the homologous recombination (HR) pathway, replication fork stabilization, clearance of trapped PARP1, and increased drug efflux, are intricate and varied. In recent years, combination therapy strategies have received considerable attention, as they can overcome treatment resistance and increase the number of patients benefiting from treatment. Preclinical and early-phase clinical studies have revealed synergistic interactions of PARPi with DNA-damaging agents, immune checkpoint inhibitors, cell cycle checkpoint inhibitors, and radiotherapy. Meanwhile, the discovery of prospective targets such as SCRN2, FGFR, and USP37 opens fresh options for reversing resistance. In order to optimize clinical treatment regimens and improve patient prognosis, this study will methodically explain the mechanism of action, resistance routes, and intervention techniques of PARPi in breast cancer.